No abstract

No abstract

No abstract

agent daratumumab (iii) outside clinical trials. The response categories were defined according to the International Myeloma Working Group consensus criteria. OS and PFS were estimated using the Kaplan-Meier method. Safety was evaluated through the rate of infusion related reactions (IRR) and adverse events (AE). Results: 41 consecutive pts were analyzed. The median age was 68 years, including 7 pts (17%) older than 75 years. Eight pts (20%) had ECOG performans status >2. Ten (24%) had high-risk cytogenetic, and 13 (32%) had extra-medullary disease. The median number of prior therapies was 4 (range 2-9). All pts were previously exposed to PI and IMID, 59% were refractory to both PI and IMID and 95% refractory to IMID. All pts were refractory to the last line of therapy. The ORR was 24.4% (10/41), including 4.9% VGPR (2/41). At a median follow-up time of 6.5 months, all pts had discontinued daratumumab because of disease progression. The median PFS was 1.9 months (CI 1.4-2.5). For pts achieving partial response or better, the median PFS was 10.1 months ). Median time to response for those patients was 1.2 months (CI 1.0-1.8), and median response duration was 9.0 months

No abstract